Loading...

MedXY AI/MedXY News/Tag: heart failure

MedXY News

EnglishTag

heart failure

147 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status

M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status

The RESHAPE-HF2 trial reveals that mitral transcatheter edge-to-edge repair (M-TEER) significantly reduces cardiovascular risks and enhances health status across all baseline patient conditions, reinforcing its role as a key intervention fo

Section: CardiologyJan 4, 2026

Beyond Arrhythmia: High-Risk Genotypes in Dilated Cardiomyopathy Predict Progression to Advanced Heart Failure

Beyond Arrhythmia: High-Risk Genotypes in Dilated Cardiomyopathy Predict Progression to Advanced Heart Failure

A landmark Spanish study reveals that patients with ‘arrhythmic’ genotypes in dilated cardiomyopathy face a significantly higher risk of advanced heart failure events, including heart transplantation and VAD implantation, necessitating a pa

Section: CardiologyJan 4, 2026

Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia

Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia

A large-scale study of US veterans demonstrates that oral magnesium therapy significantly improves outcomes in heart failure patients with hypomagnesemia, especially those with levels below 1.3 mg/dL. Conversely, supplementation in normomag

Section: CardiologyJan 2, 2026

Hypermagnesemia as a Potent Predictor of Adverse Outcomes in Heart Failure: New Evidence from the GALACTIC-HF Trial

Hypermagnesemia as a Potent Predictor of Adverse Outcomes in Heart Failure: New Evidence from the GALACTIC-HF Trial

A secondary analysis of the GALACTIC-HF trial demonstrates that hypermagnesemia, rather than hypomagnesemia, is significantly associated with increased cardiovascular death and worsening heart failure in patients with HFrEF, challenging cur

Section: CardiologyJan 1, 2026

Cardiac Myosin Activation Across the Lifespan: Age-Based Efficacy and Safety of Omecamtiv Mecarbil in HFrEF

Cardiac Myosin Activation Across the Lifespan: Age-Based Efficacy and Safety of Omecamtiv Mecarbil in HFrEF

This review synthesizes findings from the GALACTIC-HF trial regarding the efficacy and safety of omecamtiv mecarbil across age groups, highlighting its benefits in older patients and those with severe heart failure.

Section: CardiologyDec 28, 2025

A Universal Threshold? High-Sensitivity Troponin I Emerges as a Robust Prognostic Tool in Wild-Type Transthyretin Amyloid Cardiomyopathy

A Universal Threshold? High-Sensitivity Troponin I Emerges as a Robust Prognostic Tool in Wild-Type Transthyretin Amyloid Cardiomyopathy

A multicenter study identifies 80 ng/L as a critical hs-cTnI threshold for mortality risk in wild-type transthyretin amyloid cardiomyopathy, offering a standardized approach for staging and prognosis across various diagnostic assays.

Section: CardiologyDec 27, 2025

Redefining Iron Deficiency in Heart Failure: Why TSAT and Serum Iron Outperform Ferritin for Prognosis

Redefining Iron Deficiency in Heart Failure: Why TSAT and Serum Iron Outperform Ferritin for Prognosis

Recent large-scale studies, including HEART-FID and major national registries, demonstrate that transferrin saturation (TSAT) and serum iron levels are more accurate predictors of functional capacity and mortality in heart failure than trad

Section: CardiologyDec 27, 2025

Beyond Sodium Restriction: Legumes and Vegetables Linked to Improved Outcomes in Heart Failure

Beyond Sodium Restriction: Legumes and Vegetables Linked to Improved Outcomes in Heart Failure

A substudy of the global G-CHF registry demonstrates that higher intake of legumes and vegetables significantly reduces the risk of death and hospitalization in heart failure patients, while refined grains increase risk, highlighting the im

Section: CardiologyDec 27, 2025

Elevated Natriuretic Peptides: A Potent Predictor of Heart Failure and Mortality in Asymptomatic Diabetes

Elevated Natriuretic Peptides: A Potent Predictor of Heart Failure and Mortality in Asymptomatic Diabetes

A large-scale cohort study demonstrates that screening natriuretic peptide levels in individuals with type 1 or type 2 diabetes significantly predicts incident heart failure and death, advocating for routine biomarker-based risk stratificat

Section: CardiologyDec 26, 2025

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated o

Section: CardiologyDec 26, 2025

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood p

Section: CardiologyDec 26, 2025

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio

Section: CardiologyDec 26, 2025

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

The Cardiac CARE trial reveals that high-sensitivity cardiac troponin I levels do not correlate with cumulative anthracycline dose and only weakly predict subsequent declines in left ventricular function, challenging existing risk-stratific

Section: CardiologyDec 26, 2025

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyo

Section: CardiologyDec 26, 2025

Redefining Severity in Tricuspid Regurgitation: Why CMR-Derived Regurgitant Fraction and Liver Mapping Are the New Prognostic Gold Standards

Redefining Severity in Tricuspid Regurgitation: Why CMR-Derived Regurgitant Fraction and Liver Mapping Are the New Prognostic Gold Standards

A landmark study in Circulation reveals that CMR-quantified tricuspid regurgitant fraction (TRF) ≥20% significantly increases mortality risk, while liver extracellular volume (L-ECV) mapping provides a novel, potent biomarker for systemic c

Section: CardiologyDec 25, 2025

Beyond Traditional Risk Scores: How Preclinical Measures Refine Heart Failure Prediction in the ARIC Study

Beyond Traditional Risk Scores: How Preclinical Measures Refine Heart Failure Prediction in the ARIC Study

Recent findings from the ARIC study reveal that integrating cardiac biomarkers and echocardiography with the PREVENT-HF score significantly enhances the prediction of incident heart failure, identifying high-risk individuals who traditional

Section: CardiologyDec 25, 2025

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic

Section: CardiologyDec 24, 2025

Heart Failure Mortality: The Resilient Challenge in an Era of Declining Cardiovascular Deaths

Heart Failure Mortality: The Resilient Challenge in an Era of Declining Cardiovascular Deaths

This multi-national analysis of 2.92 million deaths highlights a concerning trend: while coronary and stroke mortality have plummeted, heart failure mortality remains stagnant or rising, with people with diabetes bearing a disproportionate

Section: CardiologyDec 20, 2025

Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms: A Multinational Cohort Review

Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms: A Multinational Cohort Review

This review evaluates AI algorithms predicting heart failure risk from noisy single-lead ECGs, synthesizing evidence from large multinational cohorts, highlighting improved risk stratification with AI-ECG models beyond traditional clinical

Section: AIDec 5, 2025

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was

Section: CardiologyDec 5, 2025

Prev 1 3 4 5 6 7 8 Next

MedXY News - heart failure